{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:54:19Z","timestamp":1792068859072,"version":"4.4.0"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.bmcl.2026.130779","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:46:03Z","timestamp":1789627563000},"page":"130779","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of potent, selective, and orally bioavailable monocyclic pyridine-based PKMYT1 inhibitors that synergize with CHK1 inhibition in replication-stressed cancer cells"],"prefix":"10.1016","volume":"142","author":[{"given":"Ying","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhu","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonggang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongchuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyou","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2026.130779_bb0005","article-title":"Myt1 kinase inhibitors - insight into structural features, offering potential frameworks","volume":"391","author":"Pavlovi\u0107","year":"2024","journal-title":"Chem Biol Interact"},{"issue":"12","key":"10.1016\/j.bmcl.2026.130779_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/molecules22122045","article-title":"Regulation of G2\/M transition by inhibition of WEE1 and PKMYT1 kinases","volume":"22","author":"Schmidt","year":"2017","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130779_bb0015","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4161\/cc.1.6.257","article-title":"Therapeutic exploitation of checkpoint defects in cancer cells lacking p53 function","volume":"1","author":"Dixon","year":"2002","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bmcl.2026.130779_bb0020","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41586-022-04638-9","article-title":"CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition","volume":"604","author":"Gallo","year":"2022","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130779_bb0025","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmcl.2026.130779_bb0030","doi-asserted-by":"crossref","first-page":"17997","DOI":"10.1021\/acs.jmedchem.4c01619","article-title":"Targeting protein kinase, membrane-associated tyrosine\/threonine 1 (PKMYT1) for precision cancer therapy: from discovery to clinical trial","volume":"67","author":"Yang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130779_bb0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1002186","article-title":"Overexpression of PKMYT1 associated with poor prognosis and immune infiltration may serve as a target in triple-negative breast cancer","volume":"12","author":"Li","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.bmcl.2026.130779_bb0040","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bbrc.2022.11.084","article-title":"Knockdown of PKMYT1 is associated with autophagy inhibition and apoptosis induction and suppresses tumor progression in hepatocellular carcinoma","volume":"640","author":"Wu","year":"2023","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"10.1016\/j.bmcl.2026.130779_bb0045","first-page":"4210","article-title":"Overexpression of PKMYT1 indicates the poor prognosis and enhances proliferation and tumorigenesis in non-small cell lung cancer via activation of notch signal pathway","volume":"23","author":"Sun","year":"2019","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130779_bb0050","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s12013-023-01158-9","article-title":"PKMYT1: a potential target for CCNE1 amplificated colorectal tumors","volume":"81","author":"Fang","year":"2023","journal-title":"Cell Biochem Biophys"},{"issue":"11","key":"10.1016\/j.bmcl.2026.130779_bb0055","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.celrep.2015.11.021","article-title":"Genome-wide CRISPR-Cas9 screens reveal loss of redundancy between PKMYT1 and WEE1 in glioblastoma stem-like cells","volume":"13","author":"Toledo","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.bmcl.2026.130779_bb0060","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/s44321-024-00060-y","article-title":"Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinoma","volume":"16","author":"Wang","year":"2024","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.bmcl.2026.130779_bb0065","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.926755","article-title":"Overexpression of PKMYT1 facilitates tumor development and is correlated with poor prognosis in clear cell renal cell carcinoma","volume":"26","author":"Chen","year":"2020","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.bmcl.2026.130779_bb0070","doi-asserted-by":"crossref","first-page":"10251","DOI":"10.1021\/acs.jmedchem.2c00552","article-title":"Discovery of an orally bioavailable and selective PKMYT1 inhibitor, RP-6306","volume":"65","author":"Szychowski","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130779_bb0075","author":"ClinicalTrials.gov"},{"key":"10.1016\/j.bmcl.2026.130779_bb0080","doi-asserted-by":"crossref","first-page":"15816","DOI":"10.1021\/acs.jmedchem.4c01458","article-title":"Structure-based drug design of 2-amino-[1,1\u2032-biphenyl]-3-carboxamide derivatives as selective PKMYT1 inhibitors for the treatment of CCNE1-amplified breast cancer","volume":"67","author":"Wang","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130779_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117025","article-title":"Discovery of pyrrolopyrimidinone derivatives as potent PKMYT1 inhibitors for the treatment of cancer","volume":"281","author":"Wang","year":"2025","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130779_bb0090","first-page":"228","article-title":"Discovery of PKMYT1 inhibitors with a novel scaffold for the treatment of triple-negative breast cancer","volume":"69","author":"Huang","year":"2026","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130779_bb0095","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1021\/acs.jmedchem.5c01298","article-title":"Discovery of tetracyclic derivatives as highly potent, selective, and bioavailable PKMYT1 inhibitors for cancer therapy","volume":"69","author":"Zhu","year":"2026","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130779_bb0100","doi-asserted-by":"crossref","first-page":"8497","DOI":"10.1021\/acs.jmedchem.5c00114","article-title":"Discovery of naphthyridinone derivatives as selective and potent PKMYT1 inhibitors with antitumor efficacy","volume":"68","author":"Chen","year":"2025","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130779_bb0105","doi-asserted-by":"crossref","unstructured":"Wang L, Wu Y, Deng Y, et al. Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field. J Am Chem Soc 2015; 137(8): 2695\u20132703. https:\/\/pubs.acs.org\/doi\/https:\/\/doi.org\/10.1021\/ja512751q.","DOI":"10.1021\/ja512751q"},{"issue":"9","key":"10.1016\/j.bmcl.2026.130779_bb0110","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1002\/jps.23614","article-title":"Plasma protein binding: from discovery to development","volume":"102","author":"Bohnert","year":"2013","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130779_bb0115","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"38","key":"10.1016\/j.bmcl.2026.130779_bb0120","doi-asserted-by":"crossref","first-page":"23336","DOI":"10.1073\/pnas.1922788117","article-title":"CSF1R inhibition by a small-molecule inhibitor is not microglia specific; affecting hematopoiesis and the function of macrophages","volume":"117","author":"Lei","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2026.130779_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"13","key":"10.1016\/j.bmcl.2026.130779_bb0130","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood-2014-01-453134","article-title":"Src family kinases: at the forefront of platelet activation","volume":"124","author":"Senis","year":"2014","journal-title":"Blood"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26002465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26002465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:34:52Z","timestamp":1792067692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26002465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":26,"alternative-id":["S0960894X26002465"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130779","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of potent, selective, and orally bioavailable monocyclic pyridine-based PKMYT1 inhibitors that synergize with CHK1 inhibition in replication-stressed cancer cells","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130779","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130779"}}